Vertex Pharmaceuticals Inc.

VRTX · Nasdaq · ·

Comparar

538,53 US$-0,8 %cierre 13 nov

Cifras hasta el 30 de septiembre de 2026, del 10-Q presentado el 3 de noviembre de 2026

1W: -1,6 %
1M: +8,0 %

Acciones de Vertex Pharmaceuticals Inc. (VRTX) — ¿es un buen negocio? — InspectStocks

Vertex Pharmaceuticals Inc.

VRTX · Nasdaq · ·

Comparar

538,53 US$-0,8 %cierre 13 nov

Cifras hasta el 30 de septiembre de 2026, del 10-Q presentado el 3 de noviembre de 2026

1W: -1,6 %
1M: +8,0 %

Just reported

Q3 2026 results

From Vertex Pharmaceuticals's results release of 2 de noviembre de 2026; its quarterly report has since been filed.

Revenue
Actual
3,44B US$
+12 % y/y
+3,2 % q/q
Guided
—
No guide given
EPS, GAAP
Actual
2,56 US$
-39 % y/y
-41 % q/q
Guided
—
No guide given
Operating income, GAAP
Actual
712,9M US$
-40 % y/y
-43 % q/q
Guided
—
No guide given

Company outlook

Full year 2026

Revenue13,15B US$ – 13,25B US$+10,0 % y/y Raised +0,4 %

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Cómo gana dinero

TRIKAFTA/KAFTRIO sales75 %
ALYFTREK sales17 %
KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI sales4 %
CASGEVY sales2 %
JOURNAVX sales2 %

Los porcentajes de ingresos son estimaciones para quarter ended June 30, 2026, no cifras de un informe oficial.

Compite con

Qué vende5

ALYFTREK
A once-daily combination medicine that improves the function of the faulty protein that causes cystic fibrosis.
TRIKAFTA/KAFTRIO
A combination medicine that improves the function of the faulty protein that causes cystic fibrosis. TRIKAFTA and KAFTRIO are brand names used in different markets.
KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI
Other medicines for cystic fibrosis that improve the function of the protein involved in the disease.

Mostrar 2 más

CASGEVY
A gene-editing treatment for severe sickle cell disease and transfusion-dependent beta thalassemia. A patient's blood-forming cells are collected, edited at a manufacturing facility, and returned for infusion.
JOURNAVX
An oral, non-opioid medicine for moderate-to-severe acute pain in adults.

Quién se lo compra5

Specialty pharmacies and specialist distributors buy Vertex medicines and resell them to patients, pharmacies, health care providers, hospitals, or treatment centers.
Major wholesalers in the United States buy Vertex medicines for resale through pharmacies and health care providers.
Outside the United States, distributors, retail pharmacies, hospitals, and clinics buy or distribute medicines; some hospitals and clinics are government-owned or supported.

Mostrar 2 más

Authorized treatment centers can receive CASGEVY directly from Vertex in some markets.
Government health programs and commercial insurers decide whether to cover medicines and reimburse purchases.

En qué se apoya y qué podría romperlo

De qué depende el negocio

1The business depends substantially on cystic fibrosis medicines; sales therefore depend on continued patient use, access, and the medicines' ability to compete with other treatments.
2Vertex relies on outside manufacturers and suppliers for much of its commercial and clinical supply. CASGEVY also requires coordinated cell collection, editing, shipping, and treatment-center infusion.
3Sales depend on government programs and commercial insurers covering medicines and agreeing to reimbursement terms. The company also pays royalties on certain cystic fibrosis medicines and shares CASGEVY profits with CRISPR Therapeutics.

Qué podría salir mal

1The company identifies its cystic fibrosis medicines as a substantial source of business dependence. Competing treatments, changes in patient use, or loss of patent protection could reduce sales.
2Vertex's future products depend on clinical trials showing acceptable safety and benefit and on regulators approving them. A delay or failure in programs such as povetacicept, inaxaplin, or zimislecel could limit its ability to add new medicines.
3The company relies on complex supply chains, outside manufacturers, and treatment-center coordination, particularly for cell and gene therapies. Manufacturing or distribution problems could delay or interrupt supply.

Estados financieros completos →

Sobre Vertex Pharmaceuticals Inc.

Vertex discovers, tests, manufactures, and sells prescription medicines. Its approved medicines treat cystic fibrosis, severe sickle cell disease, transfusion-dependent beta thalassemia, and moderate-to-severe acute pain; it is also testing treatments for kidney disease, type 1 diabetes, and other conditions. It sells mainly through specialty pharmacies, distributors, and wholesalers, with some gene therapy supplied directly to treatment centers.

Sede: Boston, Massachusetts
Fundada en: 1989
Empleados: 6,400 (December 31, 2025, high)
Cotiza en: NASDAQ
Cierre del ejercicio: December 31

Construido a partir de los propios informes de Vertex Pharmaceuticals Inc. ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.

Just reported

Q3 2026 results

From Vertex Pharmaceuticals's results release of 2 de noviembre de 2026; its quarterly report has since been filed.

Revenue
Actual
3,44B US$
+12 % y/y
+3,2 % q/q
Guided
—
No guide given
EPS, GAAP
Actual
2,56 US$
-39 % y/y
-41 % q/q
Guided
—
No guide given
Operating income, GAAP
Actual
712,9M US$
-40 % y/y
-43 % q/q
Guided
—
No guide given

Company outlook

Full year 2026

Revenue13,15B US$ – 13,25B US$+10,0 % y/y Raised +0,4 %

Keep exploring

The themes Vertex Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Selección
Biotech
Por InspectStocks · 19 companies
Drug developers with approved medicines, built mainly on biologic and genetic science.
Precio, 1 año
+26,8 %
Ingresos, 1 año
+12,9 %
+13
A 8B 4 5

Highest-graded in Biotechnology

Graded A or B and worth $2B or more: A first, then the largest.

All 355 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Cómo gana dinero

TRIKAFTA/KAFTRIO sales75 %
ALYFTREK sales17 %
KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI sales4 %
CASGEVY sales2 %
JOURNAVX sales2 %

Los porcentajes de ingresos son estimaciones para quarter ended June 30, 2026, no cifras de un informe oficial.

Compite con

Qué vende5

ALYFTREK
A once-daily combination medicine that improves the function of the faulty protein that causes cystic fibrosis.
TRIKAFTA/KAFTRIO
A combination medicine that improves the function of the faulty protein that causes cystic fibrosis. TRIKAFTA and KAFTRIO are brand names used in different markets.
KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI
Other medicines for cystic fibrosis that improve the function of the protein involved in the disease.

Mostrar 2 más

CASGEVY
A gene-editing treatment for severe sickle cell disease and transfusion-dependent beta thalassemia. A patient's blood-forming cells are collected, edited at a manufacturing facility, and returned for infusion.
JOURNAVX
An oral, non-opioid medicine for moderate-to-severe acute pain in adults.

Quién se lo compra5

Specialty pharmacies and specialist distributors buy Vertex medicines and resell them to patients, pharmacies, health care providers, hospitals, or treatment centers.
Major wholesalers in the United States buy Vertex medicines for resale through pharmacies and health care providers.
Outside the United States, distributors, retail pharmacies, hospitals, and clinics buy or distribute medicines; some hospitals and clinics are government-owned or supported.

Mostrar 2 más

Authorized treatment centers can receive CASGEVY directly from Vertex in some markets.
Government health programs and commercial insurers decide whether to cover medicines and reimburse purchases.

En qué se apoya y qué podría romperlo

De qué depende el negocio

1The business depends substantially on cystic fibrosis medicines; sales therefore depend on continued patient use, access, and the medicines' ability to compete with other treatments.
2Vertex relies on outside manufacturers and suppliers for much of its commercial and clinical supply. CASGEVY also requires coordinated cell collection, editing, shipping, and treatment-center infusion.
3Sales depend on government programs and commercial insurers covering medicines and agreeing to reimbursement terms. The company also pays royalties on certain cystic fibrosis medicines and shares CASGEVY profits with CRISPR Therapeutics.

Qué podría salir mal

1The company identifies its cystic fibrosis medicines as a substantial source of business dependence. Competing treatments, changes in patient use, or loss of patent protection could reduce sales.
2Vertex's future products depend on clinical trials showing acceptable safety and benefit and on regulators approving them. A delay or failure in programs such as povetacicept, inaxaplin, or zimislecel could limit its ability to add new medicines.
3The company relies on complex supply chains, outside manufacturers, and treatment-center coordination, particularly for cell and gene therapies. Manufacturing or distribution problems could delay or interrupt supply.

Estados financieros completos →

Sobre Vertex Pharmaceuticals Inc.

Sede: Boston, Massachusetts
Fundada en: 1989
Empleados: 6,400 (December 31, 2025, high)
Cotiza en: NASDAQ
Cierre del ejercicio: December 31

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP

Company outlook

Cómo gana dinero

Compite con

Qué vende5

Quién se lo compra5

En qué se apoya y qué podría romperlo

De qué depende el negocio

Qué podría salir mal

Sobre Vertex Pharmaceuticals Inc.

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP

Company outlook

Keep exploring

The theme it is part of

Biotech

Highest-graded in Biotechnology

Grade rose recently in Healthcare

Cómo gana dinero

Compite con

Qué vende5

Quién se lo compra5

En qué se apoya y qué podría romperlo

De qué depende el negocio

Qué podría salir mal

Sobre Vertex Pharmaceuticals Inc.

Keep exploring

The theme it is part of

Biotech

Highest-graded in Biotechnology

Grade rose recently in Healthcare

Crecimiento y caja — 4 de 5

Tendencia del negocio

Precio de la acción y calificación a lo largo del tiempo